In a poster presentation entitled, "Enhanced Next Generation rPA Vaccine Induces Immunogenicity and Efficacy at Least Equivalent to AVA in the New Zealand White (NZW) Rabbit Model for Anthrax," Dr. Sherry Crowe, Director, Immunology for PharmAthene, presented an overview of non clinical animal studies of SparVax® showing, among other things, that it can induce dose-dependent protective immunity in the established rabbit model for inhalational anthrax, and was statistically non-inferior to the currently licensed anthrax vaccine, BioThrax®, when comparing survival and toxin neutralization assay (TNA) results from the nonclinical anthrax aerosol challenge model.
Sherry R. Crowe, PhD, of the Oklahoma Medical Research Foundation presented data showing that African-Americans with milder disease responded best to the vaccine, with Caucasians three times more likely to be poor responders.
Dr. Sherry Crowe, Director, Immunology at PharmAthene, discussed the results in an oral presentation entitled, "Recombinant Protective Antigen Vaccine (SparVax®) Provides Protection against Lethal Challenge with Bacillus anthracis in New Zealand White Rabbits."
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.